COYACoya Therapeutics Inc
$4.41
$0.07
(1.56%)
Closed $4.41
$0.00
(0.00%)
After Hours
Reported EarningsMay 12
Mkt Cap$105.09M
Vol116,527.00
Fundamentals
Mkt Cap
$105.09M
Volume
-
52W High
$7.75
52W Low
$3.71
PE Ratio
-4.14
Avg. Volume
160,640.55
EPS (Annual)
-$1.27
Rev/Employee
$993,219.13
Earnings
May 12
Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded extension phase of the ALSTARS Trial (ClinicalTrials.gov Identifier: NCT07161999). Patients who...
Business Wire
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces that the Company will present an overview of the ongoing ALSTARS trial...
Business Wire
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative...
Business Wire
Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...
Business Wire
Coya Therapeutics (COYA) Expected to Announce Earnings on Tuesday
Coya Therapeutics (NASDAQ:COYA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recomme...
MarketBeat
Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen raised Coya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat
Coya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Friday...
MarketBeat
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the publication of a research...
Business Wire
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative...
Business Wire
<
1
2
...
>
Advertisement|Remove ads.
Latest COYA News
ViewCoya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase
Business Wire
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
Business Wire
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Business Wire
Advertisement|Remove ads.